Keyphrases
Leukemia Patients
100%
Disease Score
85%
Plasma Fibrinogen
85%
MELD Score
85%
Decompensated Cirrhosis
85%
Chronic Myeloid Leukemia
85%
Diffuse Large B-cell Lymphoma (DLBCL)
85%
MicroRNA-21 (miR-21)
85%
Fibrinogen
68%
Imatinib Therapy
57%
Breast Cancer
57%
Chemotherapy
57%
Non-Hodgkin Lymphoma
53%
Hematological Malignancies
51%
Imatinib
50%
Breast Cancer Patients
48%
Acute Myeloid Leukemia Cells
42%
Difference Expression
42%
Therapy Response
42%
Progressive multifocal Leukoencephalopathy
42%
John Cunningham Virus
42%
Early Molecular Response
42%
R-CHOP Chemotherapy
42%
Hasford Score
42%
Chronic Lymphocytic Leukemia
42%
Disseminated Histoplasmosis
42%
Plasma miRNAs
42%
Screening Biomarker
42%
WPC Channel
42%
Carbohydrate Antigen 15-3
42%
Age-matched
42%
Scattergram
42%
Breast Cancer Stage
42%
Duration of Therapy
42%
Plasma microRNA
42%
Diagnostic Test
42%
Early Detection
42%
Neutrophil-lymphocyte Ratio
42%
Cytarabine
42%
Hematology Analyzer
42%
Estimated Glomerular Filtration Rate
42%
Cell Culture
42%
CD34+
42%
Splenomegaly
42%
Pancytopenia
42%
Lymphoma Patients
42%
Acute Myeloid Leukemia
35%
General Hospital
27%
Surabaya
24%
Immunophenotyping
23%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
End Stage Liver Disease
85%
Imatinib
85%
Chronic Myeloid Leukemia
85%
Decompensated Liver Cirrhosis
85%
Fibrinogen
85%
Diffuse Large B Cell Lymphoma
64%
Hematologic Malignancy
51%
Chronic Lymphatic Leukemia
42%
JC Virus
42%
Progressive Multifocal Leukoencephalopathy
42%
Acute Myeloid Leukemia
42%
microRNA 21
42%
Cytarabine
42%
Daunorubicin
42%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
42%
Cell Culture
42%
Breast Cancer
42%
Biological Marker
42%
Nonhodgkin Lymphoma
35%
Diseases
31%
Side Effect
21%
Cross-Sectional Study
19%
Neoplasm
14%
Creatinine
14%
Observational Study
12%
Blood Clotting Factor
12%
Blood Clotting Disorder
12%
Bleeding
12%
Hepatitis C
12%
Hepatitis B
12%
Vincristine
10%
Prednisone
10%
Cyclophosphamide
10%
Vincristine Sulfate
10%
Rituximab
10%
Doxorubicin
10%
Anemia
10%
Mefloquine
8%
Normal Human
8%
Virus Infection
8%
Ethylenediaminetetraacetic Acid
7%
Remission
7%
Myeloproliferative Disorder
7%
Carbon Dioxide
7%
Treatment Group
7%
Bone Marrow Suppression
5%
Prevalence
5%
Primary Tumor
5%
Leukopenia
5%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
58%
JC Virus
42%
Cell Culture
42%
B-Cell Chronic Lymphocytic Leukemia
42%
Progressive Multifocal Leukoencephalopathy
42%
Histoplasmosis
42%
Imatinib
42%
Chronic Myelogenous Leukemia
42%
Lymphoma Cell
42%
Acute Myeloid Leukemia
42%
Leukemia Cell
42%
Cytarabine
42%
Liposomal Daunorubicin
42%
Splenomegaly
42%
Treatment Response
42%
Pancytopenia
42%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
42%
Lymphocyte
42%
Side Effect
42%
Neutrophil
42%
Non-Hodgkin Lymphoma
32%
Prevalence
24%
Diseases
22%
Chemotherapy
21%
Chronic Myelogenous Leukemia
21%
Peripheral Blood Mononuclear Cell
21%
Vincristine
21%
Doxorubicin
21%
Prednisone
21%
Vincristine Sulfate
21%
Rituximab
21%
Cyclophosphamide
21%
Anemia
21%
Patient with Non-Hodgkins Lymphoma
21%
Observational Study
17%
Medical Record
16%
Hemophagocytic Syndrome
14%
Bone Marrow Examination
14%
Chemosensitivity
14%
Itraconazole
14%
Mycosis
14%
Human Immunodeficiency Virus Infection
14%
Immune Deficiency
14%
Immunosuppressive Drug
14%
Neoplasm
10%
Leukopenia
10%
Lymphatic Tissue
10%
Bone Marrow Suppression
10%
Primary Tumor
10%
Secondary Data
10%